Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: NGS data of FrCas9 discovery and characterization

PROVIDER: PRJNA766437 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16089100_1.fastq.gz	Fastqsanger.gz
	SRR16089100_2.fastq.gz	Fastqsanger.gz
	SRR16089101.fastq.gz	Fastqsanger.gz
	SRR16089102.fastq.gz	Fastqsanger.gz
	SRR16089103.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 175

Similar Datasets

Project description:NGS data of LtCas12a discovery and characterization

| PRJNA936284 | ENA

Project description:NGS of gene using FrCas9 in rice

| PRJNA1025872 | ENA

Project description:NGS of gene using FrCas9 in rice-2

| PRJNA1026048 | ENA

Next Generation Sequencing Facilitates Quantitative Analysis of osteogenic differentiation treated with metformin

Project description:Purpose: Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to determine the differentially expressed genes of osteogenic differentiation after treatment with metformin by using NGS-derived transcriptome profiling (RNA-seq) Methods: Osteogenic mRNA profiles of MC3T3-E1 cells treated in osteogenic medium and in osteogenic medium with metformin, in triplicate, using Illumina instrument. Results: Using an optimized data analysis workflow, the data reveals 1946 up-regulated and 1544 down-regulated genes after metformin treatment. Conclusions: Our study represents the first detailed analysis of osteogenic transcriptomes after metformin treatment, with biologic replicates, generated by RNA-seq technology. We conclude that RNA-seq based transcriptome characterization would contribute the target prediction and drug discovery.

2022-03-11 | GSE198254 | GEO

Escherichia coli

Project description:NGS data for Systematic Discovery of Novel Type V CRISPR-Cas Systems

| PRJNA496291 | ENA

Project description:NGS Data

| PRJNA861380 | ENA

A MicroRNA Next-Generation-Sequencing Discovery Assay (miND) For Genome-Scale and Absolute Quantitation of Circulating MicroRNA Biomarkers

Project description:The plasma levels of tissue-specific microRNAs can be used as prognostic and diagnostic biomarkers for chronic and acute diseases. Thereby, the combination of diverse miRNAs into biomarker signatures using multivariate statistics seems especially powerful in view to tissue and condition specific miRNA shedding into the plasma. Although Next-Generation Sequencing (NGS) technology enables to analyse circulating microRNAs on a genome-scale level, it suffers from potential biases (e.g. adapter ligation bias) and lacks absolute transcript quantitation. In order to develop a robust NGS discovery assay for genome-scale quantitation of circulating microRNAs we first evaluated the sensitivity, repeatability and ligation bias of four commercially available small RNA library preparation protocols. The protocol from RealSeq Biosciences was selected based on its performance and usability, and coupled with a novel panel of exogenous small RNA spike-in controls to enable absolute quantitation and ensure comparability of data across independent NGS experiments. The established MicroRNA Next-Generation-Sequencing Discovery Assay (miND) was validated for its relative accuracy, precision, analytical measurement range and sequencing bias and was considered fit-for-purpose for microRNA biomarker discovery. Summarized, all these criteria were met and thus our analytical platform is considered fit-for-purpose for microRNA biomarker discovery from plasma, serum, cerebrospinal fluid (CSF), synovial fluid (SF), or extracellular vesicles (EV) extracted from cell culture medium in the setting of any diagnostic, prognostic or patient stratification need.

2022-01-20 | GSE189930 | GEO

Project description:Nme2Cas9 discovery and characterization

| PRJNA482053 | ENA

Proteome-wide identification of SAPs in an industrial yeast strain

Project description:Most proteogenomic approaches for mapping single amino acid polymorphisms (SAPs) require construction of a sample-specific database containing protein variants predicted from the next-generation sequencing (NGS) data. We present a new strategy for direct SAP detection without relying on NGS data. Among the 348 putative SAP peptides identified in an industrial yeast strain, 85.6% of SAP sites were validated by genomic sequencing.

2018-04-18 | PXD003101 | Pride

Project description:DTECT NGS data

| PRJNA603357 | ENA